Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior

Ngu Khine, Dalia Mudawi, Pilar Rivera-Ortega, Colm Leonard, Nazia Chaudhuri, George A Margaritopoulos

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

BACKGROUND: A subgroup of patients with fibrotic ILD experience progression and several risk factors for ILD progression have been reported, such as male sex, older age, lower baseline pulmonary function, and a radiological or pathological pattern of usual interstitial pneumonia.

OBJECTIVE: To describe a possible new phenotype of rapidly non IPF progressive fibrosing with an IPF-like outcome.

METHODS: Three previously fit and well patients who developed a rapidly progressive ILD and died within 6 to 7 months from the initial development of respiratory symptoms.

RESULTS: Unlike what is currently known, our patients developed a severe fibrosing ILD with an IPF-like outcome despite a) being younger than the average patient with IPF, b) having received a non-IPF MDT diagnosis, c) having a non-UIP pattern on HRCT. Moreover and similarly to IPF, they failed to respond to immunosuppressive treatment which is the preferred treatment option in these cases.

CONCLUSION: We believe that patients who present with similar characteristics should be considered as likely to develop a phenotype of rapidly progressive ILD and be treated with antifibrotic medications instead of immunosuppressive ones according to the favourable treatment response to antifibrotic therapy observed in clinical trials of patients with progressive fibrosing ILDs. (Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (2): 231-233).

Original languageEnglish
Pages (from-to)231-233
Number of pages3
JournalSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Volume37
Issue number2
DOIs
Publication statusPublished - 30 Jun 2020

Bibliographical note

Copyright: © 2020 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.

Keywords

  • Adult
  • Anti-Bacterial Agents/therapeutic use
  • Disease Progression
  • Fatal Outcome
  • Forced Expiratory Volume
  • Humans
  • Immunosuppressive Agents/therapeutic use
  • Lung/diagnostic imaging
  • Lung Diseases, Interstitial/diagnosis
  • Male
  • Middle Aged
  • Phenotype
  • Pulmonary Fibrosis/diagnosis
  • Severity of Illness Index
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Failure
  • Vital Capacity

Fingerprint

Dive into the research topics of 'Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior'. Together they form a unique fingerprint.

Cite this